Moderate to severe hidradenitis suppurativa treated with biological therapies.
Hidradenitis suppurativa is a debilitating disorder that can be difficult to manage with current conventional treatment strategies. Given its association with proinflammatory cytokines there has been interest in the use of novel biological monoclonal antibodies. We describe our experience with the use of these agents in six patients in whom conventional treatment had failed, with promising response noted in some patients. A growing number of studies now highlight the efficacy of these agents.
Department of Dermatology, Liverpool Hospital, Liverpool, Australia.
Niranthari
N
Chinniah
Geoffrey David
GD
Cains
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001691:Biological Therapy; D000068800:Etanercept; D005260:Female; D017497:Hidradenitis Suppurativa / Q000188:drug therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept
biological therapy; hidradenitis suppurativa; monoclonal antibody